Articles: pandemics.
-
JMIR Public Health Surveill · May 2020
Preparation for Quarantine on the Cruise Ship Diamond Princess in Japan due to COVID-19.
Japan implemented a large-scale quarantine on the Diamond Princess cruise ship in an attempt to control the spread of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in February 2020. ⋯ There were several difficulties in implementing large-scale quarantine and obtaining medical support on the cruise ship. In the future, we need to prepare for patients' transfer and the admitting hospitals when disembarking the passengers. We recommend treating the crew the same way as the passengers to control the infection. We must also draw a plan for the future, to protect travelers and passengers from emerging infectious diseases on cruise ships.
-
J. Korean Med. Sci. · May 2020
Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients.
Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. ⋯ Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease.
-
One of WHO primary function is to control and monitor internationally the spread of infectious diseases of the common killers. After SARS-COV, the International Health Regulations (IHR) was adopted in 2005 by all 194 member states to set up national preparedness for an efficient "early alert and response system". COVID-19 is a novel virus with an unpredictable course and many uncertainties about its biological, clinical and epidemiological characteristics. COVID-19 is a game changer and calls for a revision of IHR as well as a more biological, clinical and community-cantered preparedness strategy.
-
Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient's preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.